Eliana Merle
Stock Analyst at Barclays
(3.65)
# 773
Out of 5,129 analysts
106
Total ratings
46.15%
Success rate
9.18%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eliana Merle
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals | Upgrades: Overweight | $414 → $606 | $461.24 | +31.38% | 1 | Jan 28, 2026 | |
| QURE uniQure | Initiates: Equal-Weight | $31 | $24.11 | +28.58% | 5 | Jan 28, 2026 | |
| TYRA Tyra Biosciences | Initiates: Overweight | $59 | $29.99 | +96.73% | 2 | Jan 28, 2026 | |
| TPG TPG Inc. | Initiates: Overweight | $78 | $49.67 | +57.04% | 1 | Jan 28, 2026 | |
| SGMT Sagimet Biosciences | Initiates: Equal-Weight | $8 | $5.25 | +52.38% | 2 | Jan 28, 2026 | |
| PTCT PTC Therapeutics | Upgrades: Overweight | $68 → $119 | $70.92 | +67.79% | 1 | Jan 28, 2026 | |
| MBX MBX Biosciences | Initiates: Overweight | $66 | $35.00 | +88.57% | 1 | Jan 28, 2026 | |
| MDGL Madrigal Pharmaceuticals | Initiates: Overweight | $964 | $481.00 | +100.42% | 6 | Jan 28, 2026 | |
| IVA Inventiva | Initiates: Overweight | $18 | $6.19 | +190.79% | 2 | Jan 28, 2026 | |
| INSM Insmed | Initiates: Overweight | $231 | $148.43 | +55.63% | 1 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $2.35 | +282.98% | 4 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $342 | $221.49 | +54.41% | 3 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $33 | $9.25 | +256.76% | 1 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $80 | $73.33 | +9.10% | 5 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $24 | $22.29 | +7.67% | 9 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $527 | $322.28 | +63.52% | 4 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $40 → $34 | $40.51 | -16.07% | 9 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $26 → $24 | $4.63 | +418.36% | 2 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $8 → $9 | $57.72 | -84.41% | 4 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $20 | $55.25 | -63.80% | 5 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $113 → $114 | $60.31 | +89.02% | 3 | Aug 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $45 → $12 | $17.96 | -33.18% | 1 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $8 | $2.00 | +300.00% | 1 | Jul 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $74 → $21 | $13.09 | +60.43% | 6 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $70 | $82.27 | -14.91% | 3 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5 → $2.2 | $2.43 | -9.47% | 4 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $71 | $97.99 | -27.54% | 2 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $97 → $131 | $109.38 | +19.77% | 6 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3 → $5 | $22.91 | -78.18% | 3 | Apr 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $18 | $38.64 | -53.42% | 2 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $18.96 | +16.03% | 1 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $47 | $8.50 | +452.94% | 1 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $14.31 | +11.81% | 2 | May 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $192 → $134 | $34.09 | +293.08% | 3 | Aug 19, 2020 |
Vertex Pharmaceuticals
Jan 28, 2026
Upgrades: Overweight
Price Target: $414 → $606
Current: $461.24
Upside: +31.38%
uniQure
Jan 28, 2026
Initiates: Equal-Weight
Price Target: $31
Current: $24.11
Upside: +28.58%
Tyra Biosciences
Jan 28, 2026
Initiates: Overweight
Price Target: $59
Current: $29.99
Upside: +96.73%
TPG Inc.
Jan 28, 2026
Initiates: Overweight
Price Target: $78
Current: $49.67
Upside: +57.04%
Sagimet Biosciences
Jan 28, 2026
Initiates: Equal-Weight
Price Target: $8
Current: $5.25
Upside: +52.38%
PTC Therapeutics
Jan 28, 2026
Upgrades: Overweight
Price Target: $68 → $119
Current: $70.92
Upside: +67.79%
MBX Biosciences
Jan 28, 2026
Initiates: Overweight
Price Target: $66
Current: $35.00
Upside: +88.57%
Madrigal Pharmaceuticals
Jan 28, 2026
Initiates: Overweight
Price Target: $964
Current: $481.00
Upside: +100.42%
Inventiva
Jan 28, 2026
Initiates: Overweight
Price Target: $18
Current: $6.19
Upside: +190.79%
Insmed
Jan 28, 2026
Initiates: Overweight
Price Target: $231
Current: $148.43
Upside: +55.63%
Jan 28, 2026
Initiates: Overweight
Price Target: $9
Current: $2.35
Upside: +282.98%
Jan 28, 2026
Initiates: Overweight
Price Target: $342
Current: $221.49
Upside: +54.41%
Jan 28, 2026
Initiates: Overweight
Price Target: $33
Current: $9.25
Upside: +256.76%
Jan 28, 2026
Initiates: Overweight
Price Target: $80
Current: $73.33
Upside: +9.10%
Jan 28, 2026
Initiates: Equal-Weight
Price Target: $24
Current: $22.29
Upside: +7.67%
Jan 28, 2026
Initiates: Overweight
Price Target: $527
Current: $322.28
Upside: +63.52%
Jan 7, 2026
Assumes: Neutral
Price Target: $40 → $34
Current: $40.51
Upside: -16.07%
Aug 13, 2025
Maintains: Buy
Price Target: $26 → $24
Current: $4.63
Upside: +418.36%
Aug 12, 2025
Maintains: Neutral
Price Target: $8 → $9
Current: $57.72
Upside: -84.41%
Aug 12, 2025
Maintains: Neutral
Price Target: $18 → $20
Current: $55.25
Upside: -63.80%
Aug 5, 2025
Maintains: Buy
Price Target: $113 → $114
Current: $60.31
Upside: +89.02%
Jul 21, 2025
Downgrades: Neutral
Price Target: $45 → $12
Current: $17.96
Upside: -33.18%
Jul 15, 2025
Maintains: Buy
Price Target: $4 → $8
Current: $2.00
Upside: +300.00%
May 15, 2025
Maintains: Buy
Price Target: $74 → $21
Current: $13.09
Upside: +60.43%
May 13, 2025
Maintains: Buy
Price Target: $72 → $70
Current: $82.27
Upside: -14.91%
Jan 28, 2025
Maintains: Neutral
Price Target: $5 → $2.2
Current: $2.43
Upside: -9.47%
Jan 8, 2025
Maintains: Buy
Price Target: $65 → $71
Current: $97.99
Upside: -27.54%
Sep 18, 2024
Maintains: Neutral
Price Target: $97 → $131
Current: $109.38
Upside: +19.77%
Apr 4, 2024
Maintains: Neutral
Price Target: $3 → $5
Current: $22.91
Upside: -78.18%
Mar 27, 2024
Maintains: Buy
Price Target: $19 → $18
Current: $38.64
Upside: -53.42%
Oct 13, 2022
Initiates: Buy
Price Target: $22
Current: $18.96
Upside: +16.03%
Jun 23, 2022
Maintains: Buy
Price Target: $51 → $47
Current: $8.50
Upside: +452.94%
May 21, 2021
Initiates: Buy
Price Target: $16
Current: $14.31
Upside: +11.81%
Aug 19, 2020
Maintains: Neutral
Price Target: $192 → $134
Current: $34.09
Upside: +293.08%